Arctic Vision announced that it will expand its exclusive license agreement with Eyenovia, Inc. to include a third asset, MydCombi, for development and commercialization in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea. MydCombi (Arctic Vision's project code ARVN004) is Eyenovia's proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for mydriasis (pupil dilation). MydCombi was developed leveraging the Optejet® dispenser, Eyenovia's proprietary microdose array print (MAP) formulation and delivery platform, to ensure consistent and easy application of two mydriatic medications in a quick, high-precision, and touchless, micro-mist application. Pharmacologic mydriasis (pupil dilation) is part of the comprehensive eye exam, and is essential for diabetic retinopathy, glaucoma and retina disease screening. In two completed Phase III pivotal trials with MydCombi, approximately 94% of treated eyes achieved rapid, sustained, and clinically significant mydriasis post-installation, and less than 1% of subjects reported stinging as an adverse event. In the U.S., the New Drug Application (NDA) for MydCombi has been accepted for filing by the Food and Drug Administration (FDA) with PDUFA date scheduled for October 28th, 2021.